Alzheimer's Disease Clinical Research Trials

Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

Sun City : Banner Sun Health Research Institute

A pilot phase IV open label study investigating the safety and tolerability of Aricept 23mg once daily in patients with moderate to severe AD taking Exelon patch 9.5mg daily.

Sun City : Banner Sun Health Research Institute

Alzheimer's Disease Neuroimaging Initiative 2 (ADNI2)

Sun City : Banner Sun Health Research Institute

Sample Registry: Serial Alzheimer's disease and MCI Prospective Longitudinal Evaluation Longitudinal cognition follow-up and serial DNA/RNA/Serum/Plasma/CSF banking in subjects with MCI or Mild Alzheimer's disease.

Sun City : Banner Sun Health Research Institute

Twenty-Four-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fixed dose Regimens of Thalidomide and Placebo on Cerebral Spinal Fluid and Plasma Biomarkers in Patients with Mild to Moderate Alzheimer’s Disease

Phoenix : Investigational Site

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Phoenix : Banner Alzheimer Institute

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Sun City : Investigational Site

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Sun City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Sun City : Banner Sun Health Research Institute

Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

Tucson : Investigational Site

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Tuscon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Little Rock : Clinical Trials, Inc.

Mild to Moderate Alzheimer's disease

Encino : Pharmacology Research Institute, Encino

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of MABT5102A in Patients with Mild to Moderate Alzheimer’s Disease

Encino : Pharmacology Research Institute, Encino

Study of an investigational medication for the treatment of Alzheimer's Disease

Fresno : The Margolin Brain Institute

Alzheimer's Disease

Fresno : The Margolin Brain Institute

Do you know someone with Alzheimer’s disease?

Fresno : The Margolin Brain Institute

Please Take Note of Our Alzheimer’s Clinical Research Study

Glendale : California Clinical Trials Medical Group, Inc.

Alzheimer's Disease Study

Los Alamitos : Pharmacology Research Institute, Los Alamitos

Study of an investigational medication for the treatment of Alzheimer's Disease

Newport Beach : Pharmacology Research Institute, Newport Beach

Study of an investigational medication for mild to moderate Alzheimer's Disease

Newport Beach : Pharmacology Research Institute, Newport Beach

Study of an investigational medication for the treatment of Alzheimer's Disease

Sacramento : Sutter Institute for Medical Research (SIMR)

Mild Cognitive Impairment

Santa Ana : Apex Research Institute

Alzheimers? Be a Part of Research.

Santa Rosa : Radiant Research - Santa Rosa

Alzheimer's Disease Research Study

Sherman Oaks : California Neuroscience Research Medical Group, Inc.

Research study of an investigational medication or inactive placebo added to donepezil (Aricept®) for mild to moderate Alzheimer’s Disease.

Aliso Viejo : Avanir Pharmaceuticals

PRISM Registry: Pseudobulbar Affect Registry Series

Encino :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Fresno :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Garden Grove :

A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study

Glendale : Call for Information (Investigational Site 0004) Updated

A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])

Glendale : Glendale Adventist Medical Center

Single Ascending Dose Study of BIIB037 in Subjects With Alzheimer's Disease

La Jolla :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Laguna Hills : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Los Angeles :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Los Angeles : Investigational Site

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Los Angeles : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Los Angeles : University of California, Los Angeles

Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

Newport Beach :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Palo Alto : Investigational Site

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Sacramento :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

San Diego :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

San Diego : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

San Diego : University of California, San Diego

Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

San Francisco :

A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study

San Francisco :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

San Francisco : Pfizer Investigational Site

Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease

San Francisco : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

San Francisco :

VI-1121 for the Treatment Alzheimer's Disease

Santa Monica : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Santa Monica :

VI-1121 for the Treatment Alzheimer's Disease

Valencia : Sanguine Biosciences

A Biospecimen and Clinical Data Study on Patients With Alzheimer's, Multiple Sclerosis, Parkinson's, and Huntington's, for Drug & Biomarker Discovery

Boulder : Alpine Clinical Research Center

New Medication Aimed to Slow the Progression of Alzheimer’s disease

Boulder : Alpine Clinical Research Center

PET scan using an investigational radioactive drug to help determine the likely cause of cognitive decline.

Waterbury : Chase Medical Research, LLC

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E4 Non-Carriers.

Hamden : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

New Haven :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

New Haven : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Norwalk : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Fort Myers : Clinical Physiology Associates

Mild to Moderate Alzheimer Disease

Miami : Biomedical Research Alliance of New York

People with mild to moderate Alzheimer’s Disease are asked to participate in a research study being conducted by Pharmax Research Clinic, Inc.

Ocala : Renstar Medical Research

Alzheimer's Disease

Palm Beach Gardens : Palm Beach Neurological Center

Alzheimer's study

St. Petersburg : Meridien Research

Alzheimer's Disease

Tampa : Axiom Clinical Research of Florida

A clinical research study for patients with Mild Alzheimer's Disease

Bay Pines : VA Medical Center, Bay Pines

A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease

Boca Raton :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Brooksville :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Delray Beach :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Delray Beach : Site Reference ID/Investigator# 66522

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Ft Myers : Investigational Site

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Hallandale Beach : Investigational Site

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Hallandale Beach : MD Clinical

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Hallandale Beach : Pfizer Investigational Site

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Hallandale Beach : Pfizer Investigational Site Updated

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

Miami : VA Medical Center, Miami

A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease

Miami :

A Safety Study of TTP4000 in Subjects With Alzheimer's Disease

Miami :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Miami : Call for Information (Investigational Site 0002)

A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535])

Miami : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Naples :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Ocala : Pfizer Investigational Site

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Ocala : Pfizer Investigational Site Updated

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

Orlando :

A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study

Orlando :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Orlando : Call for Information (Investigational Site 0001)

A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535])

Orlando : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Orlando : Johns Hopkins

Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease

Sunrise : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Sunrise :

VI-1121 for the Treatment Alzheimer's Disease

Tampa Bay : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

West Palm Beach :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Atlanta : Neurotrials Research, Inc.

Alzheimer’s Disease

Atlanta : NeuroTrials Research, Inc.

Mild Alzheimer's disease, Mild Cognitive Impairment or dementia

Atlanta : NeuroTrials Research, Inc.

Mild Alzheimer's disease, Mild Cognitive Impairment or dementia

Atlanta : NeuroTrials Research

New Alzheimer’s Disease Research

Atlanta :

A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study

Atlanta : Pfizer Investigational Site

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Atlanta : Emory University

Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

Atlanta : Pfizer Investigational Site Updated

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

Decatur : Investigational Site

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Elk Grove Village : Alexian Brothers Hospital Network

A multinational, multicenter, randomized, double-blind, parallel-group, placebo- controlled study of the effect on cognitive performance, safety, and tolerability of SAR110894D at the doses of 0.5 mg, 2 mg, and 5 mg/day for 24 weeks in patients with mild to moderate Alzheimer's Disease on stable donepezil therapy

Elk Grove Village : Alexian Brothers Hospital Network

A phase 2 multicenter, double-blind, placebo controlled, parallel group study of PF-04447943 in subjects with mild to moderate Alzheimer's Disease on stable Donepezil therapy.

Elk Grove Village : Alexian Brothers Hospital Network

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Efficacy and Safety Trial of Bapineuzumab (AAB-001) in Subjects with Mild to Moderate Alzheimer’s Disease who are Apolipoprotein E e4 Carriers

Elk Grove Village : Alexian Brothers Hospital Network

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of MABT5102A in Patients with Mild to Moderate Alzheimer’s Diseases

Chicago : Rush Memorial University Medical Center

3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease

Elk Grove Village :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Indianapolis :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Iowa City : VA Medical Center, Iowa City

A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease

Overland Park :

A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects

Lexington : University of Kentucky Chandler Medical Center

Can Brain Waves Diagnose Alzheimer’s Disease?

Lexington : University of Kentucky Chandler Medical Center

Down Syndrome, Aging & Alzheimer's Disease Study

Louisville :

VI-1121 for the Treatment Alzheimer's Disease

Lake Charles : Lake Charles Clinical Trials

Randomized, Double blind, placebo controlled, parallel group, efficacy and safety trial of bapineuzumab in patients with mild to moderate Alzheimer's disease

New Orleans :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Baltimore : VA Maryland Health Care System, Baltimore

A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease

Baltimore : Pfizer Investigational Site

Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease

Baltimore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Bethesda : Pfizer Investigational Site

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Bethesda : Pfizer Investigational Site Updated

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

Rockville : Pfizer Investigational Site

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Rockville : Pfizer Investigational Site Updated

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

Haverhill : ActivMed Practices & Research, Inc.

Trouble Remembering?

Belmont : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Boston : VA Medical Center, Jamaica Plain Campus

A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease

Boston : Beth Israel Deaconess Medical Center

Effects of a Combined Transcranial Magnetic Stimulation (TMS) and Cognitive Training in Alzheimer Patients

Ann Arbor : VA Ann Arbor Healthcare System

A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease

Grand Rapids : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Kalamazoo : Pfizer Investigational Site

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Kalamazoo : Pfizer Investigational Site Updated

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

Traverse City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Minneapolis : VA Medical Center, Minneapolis

A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease

Hattiesburg : Hattiesburg Clinic Neurological Research Center

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Non- Carriers

Hattiesburg : Hattiesburg Clinic Neurological Research Center

Genentech ABE4955g for Mild to Moderate Alzheimer's disease

Flowood : Pfizer Investigational Site Updated

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

Hattiesburg : Investigational Site

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Creve Coeur :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Creve Coeur : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Creve Coeur : Pfizer Investigational Site

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Creve Coeur : Pfizer Investigational Site Updated

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

St. Louis : Pfizer Investigational Site

Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease

St. Louis : Pfizer Investigational Site

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

St. Louis : Pfizer Investigational Site Updated

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

Las Vegas : Cleveland Clinic Lou Ruvo Center for Brain Health

Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center

Las Vegas :

VI-1121 for the Treatment Alzheimer's Disease

Stratford : University of Medicine and Dentistry of New Jersey - School of Osteopathic Medicine

Alzheimer's disease study for mild to moderate AD.

Eatontown :

A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study

Eatontown : Investigational Site

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Eatontown : Pfizer Investigational Site

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Eatontown : Pfizer Investigational Site Updated

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

Edison : Pfizer Investigational Site

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Edison : Pfizer Investigational Site Updated

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

Mount Arlington :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Oakhurst : Pfizer Investigational Site

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Oakhurst : Pfizer Investigational Site Updated

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

Princeton :

A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study

Toms River :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Toms River :

VI-1121 for the Treatment Alzheimer's Disease

Albany :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Latham : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

New Windsor :

VI-1121 for the Treatment Alzheimer's Disease

New York :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

New York : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

New York : Fisher Alzheimer's Program, New York University School of Medicine

Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training

New York : Mount Sinai School of Medicine

Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

Rochester :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Staten Island : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Staten Island : Site Reference ID/Investigator# 66525

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Greensboro : Guilford Neurologic Associates

Impact of Florbetapir F 18 PET on the Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline

High Point : High Point Clinical Trials Center

Have you or your loved one been diagnosed with Mild Alzheimer’s with Mild Cognitive Impairment?

High Point : High Point Clinical Trials Center

Mild Cognitive Impairment or Mild Alzheimer’s Volunteers Needed

Raleigh : Multi-Specialty Research Associates of NC

Is Alzheimer’s Disease affecting your loved one?

Raleigh, : Wake Research Associates

New Clinical Research Study of Alzheimer’s Disease

Durham :

A Safety Study of TTP4000 in Subjects With Alzheimer's Disease

Durham : Duke University

Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

Durham :

VI-1121 for the Treatment Alzheimer's Disease

High Point :

A Safety Study of TTP4000 in Subjects With Alzheimer's Disease

Raleigh :

VI-1121 for the Treatment Alzheimer's Disease

Salisbury : Salisbury VAMC

A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease

Cincinnati : Community Research

Alzheimer's Disease

Toledo : Neurology & Neuroscience Center of Ohio

Alzheimer's Disease

Cleveland : VA Medical Center, Cleveland

A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease

Cleveland : Cleveland Clinic Center for Brain Health - Mellen Center

Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center

Cleveland : Case Western Reserve University

Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

Lakewood : Cleveland Clinic Senior Care Assessment - Lakewood Hospital

Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center

Toledo :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Toledo :

VI-1121 for the Treatment Alzheimer's Disease

Portland : Summit Research Network (Oregon), Inc.

Dealing with Alzheimer's can leave you wondering which way to turn

Eugene :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Portland :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Portland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Jenkintown :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Philadelphia : Pfizer Investigational Site

Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease

East Providence : Investigational Site

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Providence : Investigational Site

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Greer : Radiant Research - Greer

Clinical Research Study for Alzheimer's Disease

Charleston : Ralph H Johnson VA Medical Center, Charleston

A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease

North Charleston :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

North Charleston : Medical University of South Carolina

Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

Dallas : Texas Neurology, PA

Alzheimer's Research Study

Dallas : VA North Texas Health Care System, Dallas

A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease

Houston :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Plano :

VI-1121 for the Treatment Alzheimer's Disease

San Antonio : CEDRA Clinical Research, LLC

Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment

Salt Lake City : Lifetree Clinical Research

Alzheimer's Research Study

Salt Lake City : Call for Information (Investigational Site 0002) Updated

A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])

Salt Lake City : University of Utah

Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

Salt Lake City, UT :

A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study

Bennington :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Burlington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Burlington : Fletcher Allen Health Care-Clinical Neuroscience Research Unit

Quetiapine for the Treatment of Insomnia in Alzheimer's Disease

Roanoke : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Seattle : VA Puget Sound Health Care System, Seattle

A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease

Seattle : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Seattle : VA Puget Sound Health Care Systems

Hormone and Information Processing Study

Madison : Wlliam S. Middleton Memorial Veterans Hospital, Madison

A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease

Buenos Aires : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Ciudad Automona De Buenos Aire : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Rosario : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Santa Fe : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Chermside : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Glen Iris : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Gosford : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Heidelberg Heights : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Kogarah : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Melbourne : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Subiaco : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Hall in Tirol : Landeskrankenhaus Hall Gedächtnisambulanz

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Linz : LNK Wagner-Jauregg, Dept. of geriatrics

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Salzburg : Christian Doppler Klinik, Univ. Klinik f. Neurologie

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Vienna : MUW Klin. Pharmakologie und Klinik für Neurologie

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Vienna : MUW, Klin.Abt.f. Biolog. Psychiatrie

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Vienna : SMZ-Ost, Psychiatric Dep.

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Vienna : Studienzentrum der PROSENEX, Ambulatoriumbetriebsges.m.b.H an der Confraternität - Privatklinik Josefstadt

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Curitiba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Rio De Janeiro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

São Paulo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Sofia : GSK Investigational Site

A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease

Burlington :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Greenfield Park :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Greenfield Park : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Kelowna :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Kingston :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

London :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Montreal :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

North York :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Ottawa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Penticton :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Peterborough :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Quebec City :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Toronto : GSK Investigational Site

A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease

Verdun :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Baoding : Hebei mental health center

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Beijing : Novartis Investigative Site

A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease

Beijing : Peking University Institute of Mental Health

Memantine on Aggression and Agitation of Alzheimer's Disease (AD)

Beijing : Beijing HuiLongGuan Hospital

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Beijing : Beijing Shijitan Hospital, EMU

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Changchun : The first Affiliated Hospital of Jilin University

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Guangzhou : Guangzhou Brain Hospital

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Guilin : Affiliated Hospital of Guilin Medical University

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Hangzhou : The First Affiliated Hospital of Medical School of Zhejiang University

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Kunming : First Affiliated Hospital of Kunming Medical University

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Nanjing : Jiangsu Province Hospital

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Shanghai : Shanghai Mental Health Center

Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease

Shanghai : Shanghai Tenth People's hospital

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Shanghai : Shanghai

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Shanghai : Shanghai Changzheng Hospital

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Shanghai : Shanghai First People's Hospital

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Rijeka : Klinčki Bolnički Centar Rijeka, Klinika za Psihijatriju

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Varaždin : Opća bolnica Varaždin, Klinika za Neurologiju

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Zagreb : Psihijatrijska Bolnica Vrapče

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Zagreb : Klinčki Bolnički Centar Zagreb (REBRO), Klinika za Neurologiju

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Zagreb : "BONIFARM" Poliklinika za kliničku farmakologiju i toksikologiju

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Chocen : Policlinic

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Kladno : BRAIN-SOULTHERAPY s.r.o.

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Litoměřice : Bialbi.s.r.o. Psychiatrické oddělení

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Olomouc : Psychiatricka Ambulance

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Olomouc : Vojenska Nemocnice Psychiatricke oddeleni

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Praha : Clintrial

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Praha : PRAGTIS s.r.o.

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Praha 4 : University Thomayer Hospital

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Praha 5 : University Hospital Motol, Clinic of Neurology

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Prerov : Psychosocialni centrum

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

Turku : Clinical Research Services Turku (CRST)

Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease

Bordeaux Cedex : CMRR Hôpital Pellegrin, Bâtiment USN Tastet Girard

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Bron :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Bron : Hôpital Neurologique Pierre Wertheimer

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Caen : CHU de la Côte de Nacre

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Cahors : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Castres : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Clermont-Ferrand : CHU Clermont-Ferrand

Alzheimer and Sleep

Dijon : Centre Hospitalier Universitaire (CHU) de Dijon

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Foix Cedex : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Lavaur : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Léon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Lille : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Marseille : Hôpital Sainte-Marguerite

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Montpellier cedex : CHU Gui de Chauliac

Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers

Nantes : Hôpital Guillaume et René Laennec

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Nice : Hôpital de l'Archet

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Paris : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Paris : Pitié-Salpêtrière Hospital

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Paris : Pitié-Salpêtrière Hospital - Centre du Langage et de Neuropsychologie

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Paris : Pitié-Salpêtrière Hospital - Fédération de Neurologie

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Paris : Hôpital de la Pitié-Salpêtrière

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Paris : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Rennes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Rennes : Hôpital Pontchaillou

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Rennes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

RENNES Cedex : CHU de rennes Site Hôtel Dieu

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Rouen : Hôpital Charles Nicolle

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Saint-Brieuc : Centre Hospitalier

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Saint-Etienne : Hôpital Bellevue

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Strasbourg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Strasbourg : Hôpital Civil

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Strasbourg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Toulouse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Toulouse : Hopital La Grave

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Toulouse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Toulouse Cedex 3 : Investigational Site Number 250002 Updated

Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients

Tours : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Vic-En-Bigorre : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Achim : GSK Investigational Site

A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease

Alzenau : GSK Investigational Site

A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease

Berlin : Charite Universitätsmedizin Berlin, Klinik u. Hochschulambulanz f. Psychiatrie u. Psychotherapie

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Berlin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Ellwangen : GSK Investigational Site

A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease

Hamburg : Universitätsklinikum Hamburg-Eppendorf, Klinik für Psychiatrie und Psychotherapie

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Hamburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Hannover : GSK Investigational Site

A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease

Hannover : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Koeln : GSK Investigational Site

A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease

Leipzig : Arzneimittelforschung Leipzig GmbH, Studienzentrum

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Mannheim : Zentralinstitut für Seelische Gesundheit, Abt. Gerontopsychiatrie

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Mannheim : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Munchen :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Munich : Klinik u. Poliklinik f. Psychiatrie u. Psychotherapie der TU München

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Munich : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Nürnberg : Studienzentrum PD Dr. Steinwachs

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Nürnberg : Klinikum Nürnberg Nord, Klinik f. Psychiatrie u. Psychotherapie

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Regensburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Tubingen :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Tuebingen : GSK Investigational Site

A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease

Ulm : GSK Investigational Site

A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease

Ulm/ Donau : Studienzentrum PD Dr. Steinwachs

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Ulm/Donau : NeuroPoint GmbH

Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's Disease

Tel Aviv : Merchav Clinics

Deep Transcranial Magnetic Stimulation for Treatment of Alzheimer's Disease

Tel Aviv : Tel Aviv Sourasky Medical Center, Neurology Department

Deep Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease

Biella : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Boggiovara : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Chieti : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Genova : GSK Investigational Site

A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease

Genova : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Lido Di Camaiore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Milano : GSK Investigational Site

A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease

Milano : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Roma : GSK Investigational Site

A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease

Rome : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Adachi :